MedTrace Logo

Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis

NCT04850053 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-03-23

No results posted yet for this study

Summary

The study will investigate the biomarkers of Aβ and Tau seeds in plasma detected by Alzheimer's disease (AD) related seeds quantitative detector (AD-seeds-detector), and their sensitivity and specificity in diagnosing AD, compared with those from age-matched cognitively normal controls, and those with other types of dementia.

To perform a high throughput analysis of the amount of Aβ and Tau seeds, the investigators have developed an AD-seeds-detector, in which a fluorescence microplate reader was combined with an oscillating mixer or water-bath-type ultrasonicator.

Conditions

Sponsors & Collaborators

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Beijing Geriatric Hospital

    collaborator OTHER

  • Kaifeng Central Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Chongqing Medical Universty

    collaborator UNKNOWN

  • Huashan Hospital

    collaborator OTHER

  • First Affiliated Hospital Xi'an Jiaotong University

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Henan Provincial People's Hospital

    collaborator OTHER

  • Capital Medical University

    lead OTHER

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-26
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850053 on ClinicalTrials.gov